Objective: Type 2 diabetic patients with hemodialysis have extreme high risks of cardiovascular diseases. The lipid profile in these populations is very variable. And, the benefits of its management are not cleared. The objective of this study is to determine the use of the antihyperlipidemic agents among type 2 diabetic patients with hemodialysis at two national hospitals, Cambodia. Methods: This was a descriptive cross-sectional study conducted at Calmette and Preah Ket Mealea hospital. There were 101 patients out of 347 patients who met our criterias. Face to face interviews were held to fill the questionnaire with the agreement of the patients. The lipid profiles were checked before the hemodialysis session. The data were analysed by STATA Version 13.1. Results: Among 101 cases, female patients represented 43 (42.57%), while male patients represented 58 (57.43%). The average age of patients in the study was 62.0 (± 7.6) years. Almost 100 % of the patients in our study had multi-complications related to diabetes. Moreover, we noted that the patients had comorbidities such as hypertension 101 cases (100%) and dyslipidemia 66 cases (65.35%). Of the 66 patients, 23 (34.85%) were current and regular antihyperlipidemic users, 28 (42.42%) were former users and 15 (22.73%) cases are never received the treatment. Among 23 cases undergoing treatment with antihyperlipidemic agent, 15 (65.22%) patients received statin before hemodialysis initiation, 7 (30.43%) patients at the time of hemodialysis initiation and 1 (4.35%) patient received after the hemodialysis initiation. Mean duration of usage was 34.4 (± 41.3) months. There were two preferences agents, Atorvastatin and Rosuvastatin (average dosage 10 mg per day). Conclusion: We observed that some type 2 diabetic patients with hemodialysis still continued statin therapy. Atorvastatin and Rosuvastatin seems to be the most prescribed antihyperlipidemic agents in our series.